Arsenal Biosciences

South San Francisco, CA · Founded 2018 · CIK 0001945638 · Biotech · Private

Programmable cell therapies for solid tumors

arsenalbio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$579M
3 Form D · Sep 2024
25 months since last filing
Contracts
—
No federal contracts on record
Patents
40
5 granted · 35 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raised· 1 of 2 same dayForm D · SEC$220,806,682
Private capital raised· 2 of 2 same dayForm D · SEC$32,999,954
Private capital raisedForm D · SEC$325,352,578
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2771Niche Biopharmaceuticals LLC—$525K
2772LACERTA THERAPEUTICS, INC.—$500K
2773StaphOff Biotech, Inc.—$25K
2774Arsenal Biosciences—$579M
2775Invivyd, Inc.—$489M
2776Recursion Pharmaceuticals, LLC—$466M
2777CARTESIAN THERAPEUTICS INC—$446M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • James AhlersExecutive Officer
  • Valentin BarsanDirector
  • Brook ByersDirector
  • Kenneth DrazanDirector · Executive Officer
  • Matthew FustDirector
  • Margaret NibbiExecutive Officer
  • Sean ParkerDirector
  • Irene PleasureExecutive Officer
  • Beth SeidenbergDirector

Patents

USPTO · 5 granted of 40
  • Synthetic Pathway Activatorsapplication
  • Synthetic Pathway Activatorsgranted
  • Novel Receptors For Transcription Regulationapplication
  • Synthetic Pathway Activatorsapplication
  • Immune Cells Having Co-expressed Shrnas And Logic Gate Systemsapplication
  • Immune Cells With Combination Gene Perturbationsapplication
  • Immune Cells Having Co-expressed Tgfbr Shrnasapplication
  • Systems Targeting Psma And CA9granted
  • Systems Of Engineered Receptors Targeting Psma And CA9application
  • Cells Comprising A Suppressor Of Gene Expression And/or A Syntheticpathway Activator And/or An Inducible Payloadapplication
  • Immune Cells Having Co-expressed Shrnas And Logic Gate Systemsapplication
  • Non-viral Homology Mediated End Joiningapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.